US immigration order strikes against biotech

Autor: Robert Langer, John M. Maraganore, David P. Schenkein, Neil Warma, Chris Adams, Chip Clark, Mark Levin, William Rastetter, Bruce A Leicher, Nancy A Thornberry, Robert I Blum, Jonathan G Rosin, Kleanthis G Xanthopoulos, Timothy D. Harris, Jeff L Cleland, Robert Forrester, Nancy Simonian, Peter Barrett, Stephen Bloch, William J Rieflin, Brian M Gallagher, Lewis Rusty Williams, Doug Doerfler, Richard Ulevitch, David R. Liu, Andrew Levin, P. Grint, Nick J Simon, Pablo J Cagnoni, Daphne Zohar, Kush M Parmar, Guy Macdonald, Corey M McCann, Stelios Papadopoulos, Michael D Clayman, Diego Miralles, Paula Cobb, John Diekman, Jeremy M Levin, Amir Nashat, Samuel G Waksal, Rachel King, Sandford Sandy Zweifach, Gail J Maderis, Ankit Mahadevia, Heather Franklin, Cary G Pfeffer, Steven K Brauer, Akshay Vaishnaw, Clay B. Siegall, Howard Furst, Jonathan S Leff, William J Rutter, Dennis J. Purcell, Mary T Szela, J C Gutierrez-Ramos, Sean A McCarthy, Elizabeth Lr Donley, Yaron Werber, Doug E Williams, Christoph Westphal, Paul Sekhri, W Eddie Martucci, Jeb Keiper, John E Osborn, Simba Gill, Bassil Dahiyat, Steven H Holtzman, Annalisa Jenkins, Saurabh Saha, Matthew J. During, Camille Samuels, Mara G Aspinall, Chad Robins, Jason P Rhodes, Herve Hoppenot, Jeff Kaplan, Michael A Narachi, Amit Rakhit, Julia C Owens, Steve M Paul, Martin Varsavsky, Mark G. Currie, Rajeev Shah, Rob Perez, H. Stewart Parker, Jeff Stein, Leonard Patrick Gage, Perry Karsen, Joel F Martin, Bob More, Matthew Perry, James G McArthur, Gregory J Flesher, Martin Tolar, Andrew Schwab, James A Geraghty, Eric L Dobmeier, Brook Byers, Vanessa King, Mason W. Freeman, Larry Miller, Marco Taglietti, Jeff Albers, Neil A Exter, Michael W Bonney, Ron Cohen, Nick Leschly, Bruce L Booth, William J Newell, Peter Kolchinsky, Ryan J Watts, Paul Laikind, Andrew G. Myers, Cedric Francois, Stephen T Isaacs, Scott Koenig, Michel Vounatsos, Tuan Ha-Ngoc, Nicholas Galakatos, George P Vlasuk, Isaac Ciechanover, Jeff Kindler, Brian M. Cali, Matthew R Patterson, Kenneth I Moch, Tom Graney, Martin Babler, Jonathan J Fleming, Mark A Goldsmith, Daniel M Bradbury, John Mendlein, Mike Powell, Nessan Bermingham, Eric Elenko, H. Robert Horvitz, Yujiro Steve Hata, Mark Pruzanski, Faheem Hasnain, Henri A. Termeer, Maxine Gowen, Scott M Rocklage, Anne VanLent, Thomas Shenk, Leslie Henshaw, Jeff Jonker, Nina Kjellson, Deborah Dunsire, Zoe Barry, Ron C Renaud, Alex Martin, Uri Lopatin, George Scangos, Jean Kim, Kartik Ramamoorthi, Michael Rosenblatt, Nagesh K Mahanthappa, Harvey F. Lodish, Paul B Bolno, Wendell Wierenga, Atul Pande, Barry Greene, Alan Levy, Adrian Ad Rawcliffe, Wende S Hutton, C Geoffrey McDonough, Vicki L. Sato, Jean-Francois Formela, David V. Goeddel, Bill Haney, Rich Heyman, James E Audia, Ron Cooper, Nina Tandon, Brett Ahrens, Julian Adams, Peter Hecht, John J Lee, Stuart L. Schreiber, Laurence E Reid, Bernat Olle, Paul Hastings, John A. Scarlett, Michael Su, David Grayzel, Ted W Love, Arnold J. Levine, Gerhard Koenig, Thomas E Hughes, Jens W Eckstein, Wendy Nelson, Vikas Goyal

Publikováno v: Nature Biotechnology. 35:204-206

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2d10770c0eb9d17bb770366663a693
https://doi.org/10.1038/nbt.3824

The Motivation

Autor: Wendell Wierenga

Publikováno v: Integrated Drug Discovery Technologies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5279bc3f736543ae85ec12796c7fa480
https://doi.org/10.1201/9780203910696.ch1

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

Autor: Wendell Wierenga, Alan Dao, Robert C. Armstrong, Barbara Belli

Publikováno v: Blood. 118:1538-1538

Abstract 1538 Acute myeloid leukemia patients harboring an activated FLT receptor have a poorer prognosis following standard chemotherapy treatment compared to patients with a wild type receptor. This suggests that the combination of FLT3 inhibitor w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c51b08b6c6978521a18e825f091253cb
https://doi.org/10.1182/blood.v118.21.1538.1538

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

Autor: Patrick P Zarringkar, Robert Corringham, Peter Holman, Hagop M. Kantarjian, Jorge E. Cortes, Marcel P. Devetten, Ruwanthi N. Gunawardane, Mark J. Levis, Darejan Ghirdaladze, Robert C. Armstrong, Wendell Wierenga, Mamia Zodelava, James M. Foran, Gautam Borthakur, Mohit Trikha, Norman M. Padre, Joyce James

Publikováno v: Blood. 114:636-636

Abstract 636 Activating mutations in the FLT3 RTK are present in ∼30% of AML patients (pts), who have a significantly worse prognosis than pts with wild type (WT) FLT3. AC220 is a novel 2nd generation RTK inhibitor with potent in vitro and in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c259912d789c52445f2e16518e695890
https://doi.org/10.1182/blood.v114.22.636.636

Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patients

Autor: Michael J. Bohanon, Judith A. Nicholas, Wendell Wierenga, Mark F. Leach, Charles K. Marschke, Thomas W. Pitts, Thomas J. McQuade, James A. Merritt

Publikováno v: AIDS research and human retroviruses. 7(9)

Sera were obtained from 50 individuals infected with human immunodeficiency virus type 1 or from HIV-1-uninfected individuals before or after vaccination with recombinant gp160. These sera were evaluated for activity antagonistic to the cell-killing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869368dc200eb254a7bcc6d479993cd2
https://pubmed.ncbi.nlm.nih.gov/1742081